Skip to content
Clinical Trials – home

Rare diseases

Investigational molecules

Locations

Our offerNewsroom

FinlandBack to Finland

Clinical trials in Turku – page 18

300 clinical trials in Turku, Finland across 5 research sites. Every trial is listed in the EU Clinical Trials Register and updated daily.

FinlandOur site in FinlandKliinisetTutkimukset.fi(opens in a new tab)
Turku at a glance
300
clinical trials
  • Research sites5
Type of trial
Recruitment status
Quick filters

300 trials in Turku

Open in trial search

Pneumococcal infection

Not recruiting

Study on the Safety and Immune Response of PF-07831695 and a Drug Combination for Pneumococcal Infections in Healthy Toddlers Aged 12-15 Months

Registered drugNo placebo
Countries:FinlandFinland
  • Participants:0–17 years · Healthy volunteers
  • Substances:PF-07831695
  • Sponsor:Pfizer Inc.

Meningococcal infection

Not recruiting

Study on the Safety and Immune Response of MenACYW Conjugate Vaccine Compared to a Drug Combination in Healthy Infants and Toddlers

Registered drugNo placebo
Countries:FinlandFinland
  • Participants:0–17 years · Healthy volunteers
  • Substances:N. Meningitidis Group C (Strain C11) Polysaccharide (De-O-Acetylated) Conjugated To Tetanus Toxoid
  • Sponsor:Sanofi Pasteur

Influenza+1

Not recruiting

Study on the Effectiveness and Safety of OVX836 Vaccine for Preventing Influenza in Healthy Adults Aged 18-59

Registered drug
Countries:FinlandFinland
  • Participants:18–64 years · Healthy volunteers
  • Substances:Sodium Chloride
  • Sponsor:Osivax

Respiratory syncytial virus infection

Not recruiting

Study on the Safety and Effectiveness of MK-1654 for Preventing Respiratory Syncytial Virus (RSV) in Healthy Pre-Term and Full-Term Infants

Registered drug
Countries:FinlandFinland
  • Participants:0–17 years · Healthy volunteers
  • Sponsor:Merck Sharp & Dohme LLC

Chronic graft versus host disease

Not recruiting

Study Comparing Axatilimab to Best Available Therapy for Patients with Chronic Graft-Versus-Host Disease After Two or More Treatments

InvestigationalNo placebo
Countries:FinlandFinland
  • Participants:0–17 years · 18–64 years · 65+ years
  • Substances:Axatilimab
  • Sponsor:Incyte Corp.

Type 2 diabetes mellitus+1

Not recruiting

Study on the Effectiveness of Survodutide for Weight Loss in Patients with Type 2 Diabetes and Obesity

Investigational
Countries:FinlandFinland
  • Participants:18–64 years · 65+ years
  • Substances:BI 456906
  • Sponsor:Boehringer Ingelheim Espana S.A.

Obesity

Not recruiting

Study on the Effectiveness of Survodutide for Weight Loss in Adults with Obesity Without Diabetes

Investigational
Countries:FinlandFinland
  • Participants:18–64 years · 65+ years
  • Substances:BI 456906
  • Sponsor:Boehringer Ingelheim International GmbH

Obesity

Not recruiting

Study on How Cagrilintide and Semaglutide Help People with Overweight or Obesity Reduce Weight

Investigational
Countries:FinlandFinland
  • Participants:18–64 years · 65+ years
  • Sponsor:Novo Nordisk A/S

Breast cancer+1

Not recruiting

Study of PF-07220060 and Letrozole for Adults with HR-Positive, HER2-Negative Advanced Breast Cancer Without Prior Treatment

Registered drugNo placebo
Countries:FinlandFinland
  • Participants:18–64 years · 65+ years
  • Substances:Abemaciclib
  • Sponsor:Pfizer Inc.

Ocular myasthenia

Not recruiting

Study on the Effectiveness and Safety of Efgartigimod in Adults with Ocular Myasthenia Gravis

Registered drug
Countries:FinlandFinland
  • Participants:18–64 years · 65+ years
  • Substances:Efgartigimod Alfa
  • Sponsor:Argenx

Hormone receptor positive HER2 negative breast cancer

Not recruiting

Study Comparing Elacestrant and Standard Endocrine Therapy for Patients with Early Breast Cancer at High Risk of Recurrence

Registered drugNo placebo
Countries:FinlandFinland
  • Participants:18–64 years · 65+ years
  • Substances:Anastrozole
  • Sponsor:Stemline Therapeutics Inc.

Multiple sclerosis

Not recruiting

Study on the Effects of Cladribine on Brain Cells in Patients with Multiple Sclerosis

Registered drugNo placebo
Countries:FinlandFinland
  • Participants:18–64 years
  • Substances:Cladribine
  • Sponsor:Varsinais-Suomen hyvinvointialue

Other cities in Finland

The busiest research cities in the country

All 28 cities in Finland

Clinical research in Turku

What the registry says about research in the country

01 Respiratory Diseases

Comprehensive research focusing on respiratory infections including trials for influenza, RSV, and human metapneumovirus vaccines. Studies evaluate preventive measures for vulnerable populations.

  • Influenza vaccine development
  • RSV prevention in adults and infants
  • Viral respiratory infections

Multiple trials aim to enhance protection against seasonal respiratory illnesses in different age groups.

02 Infectious Diseases

Research centered on preventing and treating various infectious conditions, including studies of meningococcal vaccines and innovative approaches to viral infections.

  • Meningococcal prevention
  • Herpes Zoster vaccination
  • Yellow fever immunity

Studies focus on developing effective vaccination strategies for different age groups and populations.

03 Metabolic Disorders

Innovative trials examining treatments for obesity and diabetes, with particular attention to weight management therapies and metabolic health improvements.

  • Weight management interventions
  • Type 2 diabetes treatments
  • Combined therapeutic approaches

Research emphasizes lifestyle modifications alongside medical interventions.

04 Oncology

Advanced research in cancer treatment, particularly focusing on breast cancer and innovative therapeutic combinations for improved patient outcomes.

  • Breast cancer therapies
  • Leukemia treatments
  • Prostate cancer interventions

Studies evaluate both targeted therapies and combination treatments.

Back to FinlandAll countries
Clinical Trials Concierge

Prefer not to search? Our Concierge searches the trials for you.

Tell us about your condition – we search every trial in Europe and connect you with the right site.